About the Journal

Biotarget

Biotarget (ISSN 2522-669X; biotarget.amegroups.com) is a peer-reviewed journal devoted to the rapid publication of high quality studies related to identifying key biotarget molecules and the application of biotarget molecules in human and animal diseases. The principal aim of Biotarget is to provide an insight for researchers to develop molecular tools and identify molecular targets for the diagnosis and treatment of a variety of diseases (including cancer, diabetes, neurodegeneration, heart disease, inflammation, immune disease and metabolic disease etc.).

The journal publishes original articles, short communications, reviews, case report and editorials, etc. The journal welcomes research on all aspects of molecular biology and molecular medicine, ranging from biochemistry to molecular physiology, molecular pathology, molecular genetics, molecular diagnostics, and molecular therapy. All material submitted to this journal undergo appropriate review via referees who are experts in this field. All materials submitted follow international guideline with regards to approval of experiments on humans and animals.

Submission Turnaround Time:
External peer review: 1-2 months.
Acceptance to Publication Ahead of Print: 20 days.
Acceptance to Publication: 1-3 months. Original Articles are listed as priority

AME Publishing Company
Address: Rm C, 16/F, Kings Wing Plaza 1, No. 3 On Kwan Street, Shatin, NT, Hong Kong
Phone: +86 20 66355775
Email: biotarget@amegroups.com